

06-09-03

GAU-1644

Box Seq

EXPRESS MAIL NO. EV 320 857 507 US



DATE OF MAILING 06/06/2003

Our File No. 09800410-0007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Trade Application of:

Hans Klingemann

Serial No. 10/008,955

Filing Date: December 7, 2001

For NATURAL KILLER CELL LINES  
AND METHODS OF USE

)  
)  
)  
)  
)  
)  
)  
)

Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL

RECEIVED

JUN 12 2003

Dear Sir:

Transmitted herewith is:


- Power of Attorney or Authorization of Agent
- Response to Notice to Comply (in duplicate)
- Statement According to 37 C.F.R. § 1.821(f)
- 1 page Sequence Listing
- Diskette with Computer Readable Form
- No additional fee is required.
- The Commissioner is hereby authorized to charge any fees associated with this communication not covered by check or credit card payment or credit any overpayment to Deposit Account No. 19-3140. A duplicate copy of this sheet is attached.

Respectfully submitted,

  
Gregory M. Zinkl, Ph.D.  
Registration No. 48,492

SONNENSCHEIN NATH & ROSENTHAL  
P. O. BOX 061080  
WACKER DRIVE STATION, SEARS TOWER  
CHICAGO, IL 60606  
(312) 876-8000

EXPRESS MAIL NO. EV 320 857 507 US



DATE OF MAILING 6/6/2003

Our File No. 09800410-0007

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: )  
Hans Klingemann )  
Serial No. 10/008,955 ) Examiner Ronald B. Schwadron  
Filing Date: December 7, 2001 ) Group Art Unit No. 1644  
For NATURAL KILLER CELL LINES )  
AND METHODS OF USE )

**RECEIVE**

JUN 12 2003

**RESPONSE TO NOTICE TO COMPLY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


TECH CENTER 1600/290

Dear Sir:


In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated April 8, 2003 (copy attached), Applicant respectfully submits a computer readable form (CRF) copy of the "Sequence Listing" and a paper copy of the "Sequence Listing". Applicant confirms that the sequence listing provided herewith does not go beyond the disclosure in the application as filed.

Please charge any deficiency or credit any overpayment in connection with this filing to our Deposit Account No. 19-3140. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

  
Gregory M. Zinkl, PH.D.  
Registration No. 48,492

SONNENSCHEIN NATH & ROSENTHAL  
P. O. BOX 061080  
WACKER DRIVE STATION, SEARS TOWER  
CHICAGO, IL 60606  
(312) 876-8000



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/008,955	12/07/2001	Hans Klingemann	72535

**CONFIRMATION NO. 5420**

22242  
FITCH EVEN TABIN AND FLANNERY  
120 SOUTH LA SALLE STREET  
SUITE 1600  
CHICAGO, IL 60603-3406

**RECEIVED**

JUN 12 2003

TECH CENTER 1600/2900

Date Mailed: 04/08/2003

**FORMALITIES LETTER**



"OC00000009794356"

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 308-2600
- For PatentIn Software Program Help, call (703) 308-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*PM*  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE